17/03/2026
Brustkrebs-Therapie: Wo steht medizinisches Cnnbis?
Von Symptomlinderung bis Studienlage – wir ordnen ein.
Quellen: �(1) Colvin, E. K., Hudson, A. L., Anderson, L. L., Kumar, R. P., McGregor, I. S., Howell, V. M., & Arnold, J. C. (2022). An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma. Cancers, 14(15), 3813. �(2) Aviram, J., Lewitus, G. M., Vysotski, Y., Amna, M. A., Ouryvaev, A., Procaccia, S., Cohen, I., Leibovici, A., Akria, L., Goncharov, D., Mativ, N., Kauffman, A., Shai, A., Bar-Sela, G., & Meiri, D. (2022). The Effectiveness and Safety of Medical C-nn-bis for Treating Cancer Related Symptoms in Oncology Patients. Frontiers in pain research (Lausanne, Switzerland), 3, 861037. �(3) Brisbois, T. D., de K**k, I. H., Watanabe, S. M., Mirhosseini, M., Lamoureux, D. C., Chasen, M., MacDonald, N., Baracos, V. E., & Wismer, W. V. (2011). Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Annals of oncology : official journal of the European Society for Medical Oncology, 22(9), 2086–2093. �(4) Zylla, D. M., Eklund, J., Gilmore, G., Gavenda, A., Guggisberg, J., Vazquez Benitez, G., Pawloski, P. A., Arneson, T., Richter, S., Birnbaum, A. K., Dahmer, S., Tracy, M., & Dudek, A. (2021). A randomized trial of medical c@nn@bis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29(12), 7471–7478.